This study is looking into whether extended-release niacin, an FDA-approved medication, can reach the brain and spinal fluid in people with mild to moderate Alzheimer's disease. Researchers want to see if niacin levels increase in your blood and spinal fluid after taking a 500 mg dose. You might receive either extended-release niacin or an inactive placebo. The study is enrolling 30 participants, aged 60 to 85, who have a diagnosis of Alzheimer's disease and are on a stable dose of other Alzheimer's medications. You also need a reliable co-participant who sees you at least three days a week. This research aims to understand if niacin could be a new way to help treat Alzheimer's.

Study design

This is a randomized, placebo-controlled, and blinded study involving 30 participants. It compares extended-release niacin (500 mg) to an inactive placebo.

What's involved

Participants will have visits at baseline and at 60 days. Pill counts will be done at the 30-day visit to check that you are taking the medication as instructed.

Compensation

Not stated in the trial record.

Follow-up

Your nicotinic acid levels will be measured at baseline and at the 60-day visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.